Oncopeptides may today present before the European Medicines Agency to explain why the regulator should recommend in favor of EU marketing approval for its multiple myeloma drug melphalan flufenamide, which has had a bumpy ride in the US following its approval there last year under the brand name Pepaxto.
The company was listed as being possibly due to speak at an oral explanation meeting this afternoon, according to the...








